151 related articles for article (PubMed ID: 8461559)
1. Human parathyroid peptide treatment of vertebral osteoporosis.
Reeve J; Arlot ME; Bradbeer JN; Hesp R; Mcally E; Meunier PJ; Zanelli JM
Osteoporos Int; 1993; 3 Suppl 1():199-203. PubMed ID: 8461559
[TBL] [Abstract][Full Text] [Related]
2. Treatment of osteoporosis with human parathyroid peptide and observations on effect of sodium fluoride.
Reeve J; Davies UM; Hesp R; McNally E; Katz D
BMJ; 1990 Aug; 301(6747):314-8. PubMed ID: 2393738
[TBL] [Abstract][Full Text] [Related]
3. Effect of treatment for 6 months with human parathyroid hormone (1-34) peptide in ovariectomized cynomolgus monkeys (Macaca fascicularis).
Jerome CP; Johnson CS; Vafai HT; Kaplan KC; Bailey J; Capwell B; Fraser F; Hansen L; Ramsay H; Shadoan M; Lees CJ; Thomsen JS; Mosekilde L
Bone; 1999 Sep; 25(3):301-9. PubMed ID: 10495134
[TBL] [Abstract][Full Text] [Related]
4. Treatment of osteoporosis with parathyroid peptide (hPTH 1-34) and oestrogen: increase in volumetric density of iliac cancellous bone may depend on reduced trabecular spacing as well as increased thickness of packets of newly formed bone.
Bradbeer JN; Arlot ME; Meunier PJ; Reeve J
Clin Endocrinol (Oxf); 1992 Sep; 37(3):282-9. PubMed ID: 1424211
[TBL] [Abstract][Full Text] [Related]
5. Periodic courses of human 1-34 parathyroid peptide alternating with calcitriol paradoxically reduce bone remodelling in spinal osteoporosis.
Reeve J; Arlot M; Price TR; Edouard C; Hesp R; Hulme P; Ashby JP; Zanelli JM; Green JR; Tellez M
Eur J Clin Invest; 1987 Oct; 17(5):421-8. PubMed ID: 3121346
[TBL] [Abstract][Full Text] [Related]
6. hPTH 1-34 treatment of osteoporosis with added hormone replacement therapy: biochemical, kinetic and histological responses.
Reeve J; Bradbeer JN; Arlot M; Davies UM; Green JR; Hampton L; Edouard C; Hesp R; Hulme P; Ashby JP
Osteoporos Int; 1991 Jun; 1(3):162-70. PubMed ID: 1790404
[TBL] [Abstract][Full Text] [Related]
7. Calcium-47 kinetic measurements of bone turnover compared to bone histomorphometry in osteoporosis: the influence of human parathyroid fragment (hPTH 1-34) therapy.
Reeve J; Arlot M; Bernat M; Charhon S; Edouard C; Slovik D; Vismans FJ; Meunier PJ
Metab Bone Dis Relat Res; 1981; 3(1):23-30. PubMed ID: 7266363
[No Abstract] [Full Text] [Related]
8. Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study.
Dempster DW; Cosman F; Kurland ES; Zhou H; Nieves J; Woelfert L; Shane E; Plavetić K; Müller R; Bilezikian J; Lindsay R
J Bone Miner Res; 2001 Oct; 16(10):1846-53. PubMed ID: 11585349
[TBL] [Abstract][Full Text] [Related]
9. A small dose of human parathyroid hormone(1-34) increased bone mass in the lumbar vertebrae in patients with senile osteoporosis.
Sone T; Fukunaga M; Ono S; Nishiyama T
Miner Electrolyte Metab; 1995; 21(1-3):232-5. PubMed ID: 7565456
[TBL] [Abstract][Full Text] [Related]
10. Treatment with parathyroid peptides and estrogen replacement for severe postmenopausal vertebral osteoporosis: prediction of long-term responses in spine and femur.
Reeve J; Mitchell A; Tellez M; Hulme P; Green JR; Wardley-Smith B; Mitchell R
J Bone Miner Metab; 2001; 19(2):102-14. PubMed ID: 11281158
[TBL] [Abstract][Full Text] [Related]
11. Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: results of a randomized controlled clinical trial.
Lane NE; Sanchez S; Modin GW; Genant HK; Pierini E; Arnaud CD
J Bone Miner Res; 2000 May; 15(5):944-51. PubMed ID: 10804025
[TBL] [Abstract][Full Text] [Related]
12. Bone densitometric and histomorphometric responses to sequential human parathyroid hormone (1-38) and salmon calcitonin in osteoporotic patients.
Hodsman AB; Steer BM; Fraher LJ; Drost DJ
Bone Miner; 1991 Jul; 14(1):67-83. PubMed ID: 1868270
[TBL] [Abstract][Full Text] [Related]
13. Effects of intermittent hPTH(1-34) alone and in combination with 1,25(OH)(2)D(3) or risedronate on endosteal bone remodeling in canine cancellous and cortical bone.
Boyce RW; Paddock CL; Franks AF; Jankowsky ML; Eriksen EF
J Bone Miner Res; 1996 May; 11(5):600-13. PubMed ID: 9157775
[TBL] [Abstract][Full Text] [Related]
14. Effects of human PTH(1-34) and bisphosphonate on the osteopenic rat model.
Tanizawa T; Yamamoto N; Takano Y; Mashiba T; Zhang L; Nishida S; Endo N; Takahashi HE; Fujimoto R; Hori M
Toxicol Lett; 1998 Dec; 102-103():399-403. PubMed ID: 10022286
[TBL] [Abstract][Full Text] [Related]
15. Preexisting bone loss associated with ovariectomy in rats is reversed by parathyroid hormone.
Liu CC; Kalu DN; Salerno E; Echon R; Hollis BW; Ray M
J Bone Miner Res; 1991 Oct; 6(10):1071-80. PubMed ID: 1796755
[TBL] [Abstract][Full Text] [Related]
16. Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal.
Cosman F; Nieves J; Woelfert L; Formica C; Gordon S; Shen V; Lindsay R
J Bone Miner Res; 2001 May; 16(5):925-31. PubMed ID: 11341338
[TBL] [Abstract][Full Text] [Related]
17. Effect of treatment for 3 months with human parathyroid hormone 1-34 peptide in ovariectomized cynomolgus monkeys (Macaca fascicularis).
Jerome CP; Johnson CS; Lees CJ
Bone; 1995 Oct; 17(4 Suppl):415S-420S. PubMed ID: 8579946
[TBL] [Abstract][Full Text] [Related]
18. Treatment with human parathyroid hormone (1-34) for 18 months increases cancellous bone volume and improves trabecular architecture in ovariectomized cynomolgus monkeys (Macaca fascicularis).
Jerome CP; Burr DB; Van Bibber T; Hock JM; Brommage R
Bone; 2001 Feb; 28(2):150-9. PubMed ID: 11182372
[TBL] [Abstract][Full Text] [Related]
19. Differing effects of PTH 1-34, PTH 1-84, and zoledronic acid on bone microarchitecture and estimated strength in postmenopausal women with osteoporosis: an 18-month open-labeled observational study using HR-pQCT.
Hansen S; Hauge EM; Beck Jensen JE; Brixen K
J Bone Miner Res; 2013 Apr; 28(4):736-45. PubMed ID: 23044908
[TBL] [Abstract][Full Text] [Related]
20. Results of a stimulatory therapy of low bone metabolism in osteoporosis with (1-38)hPTH and diphosphonate EHDP. Protocol of study I, osteoporosis trial Hannover.
Hesch RD; Heck J; Delling G; Keck E; Reeve J; Canzler H; Schober O; Harms H; Rittinghaus EF
Klin Wochenschr; 1988 Oct; 66(19):976-84. PubMed ID: 3141672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
